{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:17Z","timestamp":1753892057800,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The incidence of the ROS1 fusion mutation (ROS proto-oncogene 1) in non-small cell lung cancer (NSCLC) is approximately 1-2%. At least 55 partner genes have been identified that can fuse with ROS1.Herein, we report a case of a lung adenocarcinoma patient harboring a rare ROS1 fusion mutation with brain metastasis, who achieved good control of both lung and intracranial lesions after treatment with Entrectinib. A 68-year-old female patient with no smoking history presented with a cough and headache. She was diagnosed with advanced lung adenocarcinoma, stage T1cN3M1c IVb, which included multiple brain metastases. An IGR (downstream MAN1A1) ROS1:exon34 fusion was detected at a mutant allele frequency (MAF) of 12.73%, accompanied by two TP53 mutations c.1024C&amp;gt;T (p.R342*) and c.686_687del (p.C229Yfs*10). The resultant fusion protein preserves the whole TRKA kinase domain of ROS1, and therefore may constitutively activate ROS1.Therefore, RNA-seq was conducted to further confirm the expression of IGR-ROS1 fusion at mRNA level. A CD74:exon6 ~ ROS1: exon 35 fusion was identified, which could mediate the full kinase function. A biopsy of the right supraclavicular lymph node confirmed the diagnosis of lung adenocarcinoma. She was diagnosed with advanced lung adenocarcinoma, stage T1cN3M1c IVb, which included multiple brain metastases. The patient began treatment with entrectinib (600 mg, once daily) as a first-line therapy. At the time of diagnosis, the patient reported headaches and experienced sleep disturbances. Subsequently, the patient underwent whole-brain radiotherapy. Significant improvements were noted in her headache and insomnia symptoms. After one month, the longest diameter of the left upper lung nodule decreased from 19 mm to 12 mm, and there was a notable reduction in the right hilar and mediastinal lymph nodes. Additionally, the patient\u2019s intracranial metastatic lesion reduced in size from 19 mm to 8 mm, leading to an improvement in her headache symptoms. It is worth further exploring whether patients carrying IGR fusions can receive targeted therapy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1566687","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:12:12Z","timestamp":1744776732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib"],"prefix":"10.3389","volume":"15","author":[{"given":"Yifan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lemeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1035033","article-title":"Detection of ROS1 gene fusions using next-generation sequencing for patients with Malignancy in China","volume":"10","author":"Li","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-741","article-title":"Abstract 741: Molecular and clinicopathological characteristics of Chinese non-small cell lung cancers with ROS1 gene fusions identified by next-generation sequencing","volume":"80","author":"Gao","year":"2020","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.01.005","article-title":"Mechanism of translation initiation by Dicistroviridae IGR IRESs","volume":"411","author":"Hertz","year":"2011","journal-title":"Virology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20251","article-title":"Interstitial deletions generating fusion genes","volume":"18","author":"Panagopoulos","year":"2021","journal-title":"Cancer Genomics Proteomics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/1061186x.2022.2085730","article-title":"ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance","volume":"30","author":"Yu","year":"2022","journal-title":"J\u00a0Drug Targeting"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvae008","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer","volume":"70","author":"Zhao","year":"2024","journal-title":"Clin Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein","volume":"22","author":"Fischer","year":"2020","journal-title":"Neuro-oncology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.cllc.2023.12.001","article-title":"Brief report: updated efficacy and safety data from an integrated analysis of\u00a0entrectinib in locally advanced\/metastatic ROS1 fusion-positive non\u2013small-cell\u00a0lung cancer","volume":"25","author":"Fan","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.02.023","article-title":"Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC","volume":"15","author":"Li","year":"2020","journal-title":"J Thorac oncology: Off Publ Int Assoc Study Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:12:13Z","timestamp":1744776733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1566687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":12,"alternative-id":["10.3389\/fonc.2025.1566687"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1566687","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1566687"}}